Latest Xintela News & Updates

See the latest news and media coverage for Xintela. We track all announcements, press releases, and industry mentions in real time, all in one place.

Xintela

Biopharma company developing stem cell and cancer therapies

xintela.se

Headquarters: Lund, Sweden
Founded year: 2009
Company type: Public company
Number of employees: 20–50

Last updated Today

Latest news about Xintela

In short: Xintela reported positive safety data for XSTEM in clinical trials, secured international patents, and completed multiple capital raises.

Company announcements

May 29 Xintela

Xintela reports positive safety results from clinical study with XSTEM

No serious adverse events were reported, and the company plans to evaluate XSTEM on other wound indications.

May 29 Xintela

Xintela reports interim report for the first quarter of 2026

Net sales increased to 443 KSEK and profit before tax was -11,780 KSEK. Several advances with XSTEM and patents.

May 22 Xintela

Xintela's annual general meeting made decisions on the board and share issues

The board was re-elected with new appointments, share issue authorizations were approved, no dividend.

May 12 Xintela

Xintela granted patent in Japan for XSTEM treatment of ARDS

Patent JP 7821414 protects treatment of ARDS and is the first approval in the patent family, which strengthens partner discussions.

Media coverage

April 14 FinanzNachrichten

Xintela AB: Xintela granted US patent for XSTEM treatment of difficult-to-heal wounds and skin defects

Xintela (XINT) announces today that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of the company's stem cell...

February 27 Yahoo Finance

Xintela AB (publ) (XINT.ST)

Find the latest Xintela AB (publ) (XINT.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.

February 13 MarketWatch

Xintela AB

Visit a quote page and your recently viewed tickers will be displayed here.

30 October 2025 FinanzNachrichten

Xintela AB: Last patient dosed in Xintela's clinical study on difficult-to-heal leg ulcers

Xintela (XINT) announces that the last patient has been dosed in the company's clinical Phase I/IIa study with XSTEM® in patients with difficult-to-heal venous leg...

Never miss news about Xintela

Track Xintela and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.